Investigation Report on China Phosphocreatine Market, 2010-2019 is a new market research publication announced by Reportstack. The global epidemic trend shows that cardiovascular disease has become one of the serious threats to human health whose incidence and death rate has exceeded that of malignant tumor and leapt to the first. According to the World Health Organization (WHO), about 17 million people die of cardia-cerebrovascular disease, among which 50% die of acute myocardial infarction and cerebral infarction each year in the world. Phosphocreatine, developed by Alfa Wassermann in 1997, has the largest market share compared with other cardiovascular drugs.
According to survey, phosphocreatine develops fast after entering China with annual sales value rising from less than CNY 30 million in 2005 to CNY 1.37 billion in 2014 and CAGR during the period of 2005-2014 reaching up to 53.7%. Phosphocreatine enjoys a vast demand in China. Beijing Lifeshine Pharmaceutical Co., Ltd, Haikou Qili Pharmaceutical Co., Ltd, Hebei Tiancheng Pharmaceutical Co., Ltd, Harbin Bolai Pharmaceutical Co., Ltd and Jilin Yinglian Biopharmaceutical Co., Ltd all occupy certain shares of the market, among which Jilin Yinglian Biopharmaceutical Co., Ltd has the largest market share of over 40% with sales value in 2014 reaching up to CNY 560 million. However, Alfa Wassermann (Italy), the original developer of phosphocreatine, had a market share less than 3% in China in 2014.
Complete report available @ Investigation Report on China Phosphocreatine Market, 2010-2019
As Chinese people’s living standards improve and the population ages, the incidence of cardiovascular will keep increasing and the market size of phosphocreatine in China will keep expanding too.
Readers can get at least the following information through this report:
-market share of manufacturers of phosphocreatine in Chinese market
-price of phosphocreatine in Chinese market
-major manufacturers of phosphocreatine in China
-share of different dosage forms of phosphocreatine in Chinese market
-market outlook of phosphocreatine in China
The author suggests the following groups of people purchase this report:
-manufacturers of drugs for cardiovascular disease
-investors/ research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service
Companies Mentioned
Beijing Lifeshine Pharmaceutical Co., Ltd; Hebei Tiancheng Pharmaceutical Co., Ltd; Harbin Bolai Pharmaceutical Co., Ltd; Haikou Qili Pharmaceutical Co., Ltd; Jilin Yinglian Biopharmaceutical Co., Ltd
About Reportstack:
Reportstack is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world’s top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack members with cutting edge research products to facilitate strategic business decisions.
Contact:
Debora White
Manager – Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
Market Research Reports on Chinese Industry 